Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Sleep Apnea Devices Market - Outlook and Forecast 2022-2027
The global market for sleep apnea devices reached a value of USD 6.74 billion in 2021 and is projected to reach USD 10 billion by 2027, exhibiting a compound annual growth rate (CAGR) of 7.07%. This growth can be attributed to several factors, including the high prevalence of sleep apnea worldwide, the increasing number of potential risk factors, advancements in sleep apnea device technology, and the aging population.
Obstructive sleep apnea (OSA) is particularly prevalent among adults, with mild to moderate severity affecting around 14% of men and 5% of women. The condition is becoming more common due to the global rise in obesity rates. The estimated global prevalence of OSA is around 1 billion people, with some countries experiencing rates exceeding 50% in the general population.
|No. of Pages||
USD 6.7 billion in 2020
Product, Age Group, Gender, End-user, and Geography
|No. of Companies Mentioned||
In developed regions like North America and Europe, sleep apnea devices are already widely used for the treatment of OSA. These markets are seeing the entry of numerous new players and startups, offering a variety of products to meet customer demand and market trends. The current trend in the market is the development of smart sleep apnea devices, which are being explored by existing and new players.
The increasing prevalence of obesity and lifestyle-related diseases, coupled with the rising rate of sleep apnea diagnosis, is leading to a larger patient base in need of treatment or management options. This, combined with the growing number of sleep physicians, technicians, and clinics worldwide, is driving the growth of the global sleep apnea devices market.
The convergence of large data sets, enhanced computing power, and advancements in algorithms has opened up possibilities for the application of artificial intelligence (AI) across various industries. In the sleep apnea devices market, AI has the potential to go beyond the consideration of the apnea-hypopnea index (AHI) and take into account additional factors for better prediction of side effects and treatment response. AI can aid in screening, diagnosing, and reducing the need for costly in-lab polysomnography (PSG) tests, thus streamlining the path to effective treatment.
In recent years, the use of unattended wearable monitors for the diagnosis of OSA in adults has been addressed in guidelines by the American Academy of Sleep Medicine (AASM). Technological advancements have led to the inclusion of home sleep testing utilizing peripherals like arterial tonometry (PAT), oximetry, and actigraphy in the diagnosis of obstructive sleep.
Key players in the sleep apnea diagnostics market, such as Itamar Medical, offer devices like WatchPat that utilize proprietary PAT technology. ResMed has also introduced the Onesleeptest service for NightOwl, allowing individuals to test their sleep quality from home and receive results from a certified sleep specialist within a few business days.
Technological advancements in continuous positive airway pressure (CPAP) therapy have revolutionized the field since its inception in 1981. Modern CPAP devices are lighter, quieter, and more efficient compared to earlier models. AutoPAP devices, for example, adjust airway pressure automatically based on individual needs, ensuring the respiratory system remains open during sleep. Additionally, CPAP machines now feature advanced recording capabilities that track mask usage, air supply, and patient breathing patterns.
Another notable improvement in CPAP devices is their reduced noise levels. In addition to being lightweight, these devices deliver filtered air at a pressure of around 20 cm H2O, providing a comfortable experience for patients and their bed partners. Gone are the days of sleeping next to noisy machines; modern CPAP devices are well-insulated and designed to minimize disturbances.
The market is segmented based on various factors, including product, age group, gender, end-user, and geography.
Segmentation by Product:
Segmentation by Age Group:
Between 41 & 60 Years
61 Years & Above
Below 40 Years
Segmentation by Gender:
Segmentation by End-User:
Home Healthcare Settings
Segmentation by Geography
North America – US, Canada
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan, India, South Korea, Australia
Latin America – Brazil, Mexico, Argentina
Middle East & Africa – South Africa, Saudi Arabia, Turkey
The therapeutic devices segment holds the largest share, 73.98%, in the global market for sleep apnea devices based on product segmentation. This segment includes positive airway pressure (PAP) devices, oral appliances, adaptive servo-ventilators, implants, airway clearance systems, oxygen therapy devices, and accessories. The prevalence of obstructive sleep apnea (OSA) is increasing significantly in both developed and developing countries, primarily due to factors such as obesity, an aging population, smoking, and sedentary lifestyles. Positive airway pressure (PAP) therapy refers to treatments that use compressed air to support the airways during sleep. PAP machines continue to see technological advancements, with newer devices combining variable positive air pressure (VPAP) technology with the automatic adjustments found in dual-level pressure settings of traditional BiPAP therapy.
The market for sleep apnea devices with facial interfaces was valued at USD 916.7 million in 2021. Continuous positive airway pressure (CPAP) masks and headgear are available in different styles and sizes to cater to individual needs and face shapes. It may be necessary for patients to try different mask styles until they find one that suits them best. Masks are used to direct air from the therapy device and often have built-in vents to expel exhaled air.
In terms of age group, the market is segmented into 41-60 years, 61 years and above, and below 40 years. The 41-60 years age group accounts for a larger share, 51.06%, in the global market. This age group consists of working adults who face daily challenges both at work and at home. Common risk factors for developing OSA and related symptoms like snoring in this age group include work-related stress, alcohol consumption, chronic smoking, and obesity.
Among the gender segments, males hold the highest share, 60.50%, in the global market. OSA is a common sleep-related breathing disorder, particularly prevalent in older males. The estimated prevalence of OSA in males in North America is around 15-30%. Most patients with OSA experience daytime sleepiness and exhibit symptoms such as loud snoring, wheezing, choking, sniffling, or cessation of breathing while their bed partner sleeps. Women often report these symptoms on behalf of their partners. Obesity is a significant risk factor for sleep apnea, and most OSA patients are overweight. Regardless of baseline weight, waist size, age, or race, men are more likely than women to experience increased apnea-hypopnea index (AHI) with weight gain. The global market for sleep apnea devices targeting male users is expected to grow at a CAGR of 7.30% during the forecast period.
The sleep clinics/labs segment holds the highest share, 39.14%, among all end-users in the global market for sleep apnea devices. As the prevalence of sleep disorders increases, the demand for sleep labs also rises. Accurate diagnosis is crucial in identifying sleep disorders, and polysomnography (PSG) is the most preferred diagnostic technology due to its high medical accuracy.
The demand for sleep facilities and clinics equipped with technologically advanced PSGs has increased with the growing incidence of sleeping disorders. Since the 1970s, approximately 3,500 sleep labs or clinics have been established in the US, with about 1,400 of them accredited by the American Academy of Sleep Medicine. Research has linked sleep disturbances with an increased risk of various illnesses, including heart attack, stroke, diabetes, rheumatoid arthritis, metabolic disorders, and others.
In terms of regional segmentation, North America dominates the global market, accounting for a revenue share of 40.43% in 2021. The region’s market growth is driven by factors such as a high prevalence of sleep disorders, changes in sleep patterns, lifestyle modifications, and the presence of various vendors, including key players, start-ups, and sleep-focused companies. North America has a significant prevalence of OSA, with rates of nearly 15-30% in men and 10-15% in women. The region’s market share is further bolstered by the presence of sleep apnea device manufacturers, making it the most significant region globally.
The European sleep apnea devices market was valued at USD 1.9 billion in 2021. The market in Europe is primarily driven by the increasing use of technology to manage sleep disorders. PAP devices, innovative oral appliance therapy (OAT) devices, and diagnostic devices are gaining traction in this market. The APAC region exhibits the highest growth rate among all regions and is expected to continue growing during the forecast period. APAC’s manufacturing capabilities enable large-scale production, which influences the global sleep apnea devices market. China, Japan, and India are leading countries in the APAC sleep apnea device market, with China being the dominant player due to its innovative solutions.
The worldwide market for sleep apnea devices exhibits a high level of diversity, with a multitude of global and local companies providing a wide range of sleep apnea devices, including PAP devices, oral devices, implants, and other related products. Global players in this market are dedicated to the development of innovative solutions and the expansion of their product portfolios in order to maintain competitiveness. These companies are making significant investments in research and development as well as product development activities in order to broaden their offerings. Prominent manufacturers in the global sleep apnea devices market, such as ResMed, Koninklijke Philips N.V, BMC Medical, Natus Medical, Itamar Medical, Inspire Medical Systems, Compumedics, and Drive DeVilbiss Healthcare, focus on continuous product advancement and the introduction of sophisticated sleep apnea devices incorporating cutting-edge technologies to enhance their presence in the industry.
Key companies profiled in this report include Nihon Kohden Corporation, BMC Medical, Drive DeVilbiss Healthcare, SomnoMed, Glidewell, ResMed, Koninklijke Philips N.V, Fisher & Paykel Healthcare, Compumedics Limited, Inspire Medical Systems, Natus Medical, Itamar Medical, Apex Medical, Cadwell Industries, SOMNOmedics, Cleveland Medical Devices, ProSomnus Sleep Technologies, MEDITAS, White Dental Healthcare, Oventus, Tomed, Signifier Medical Technologies, ApneaMed, Nyxoah, Vivos Therapeutics, Somnowell, RemSleep Holdings, Siesta Medical, Horizon Prime, Nox Medical, Onera Health, LivaNova, ZOLL Medical, BRAEBON Medical, Invacare, Breas Medical.
Recent Industry Developments
Fisher & Paykel Healthcare announced the introduction of the F&P Evora Full, a compact full-face mask for obstructive sleep apnea (OSA), in the United States market in April 2022.
In June 2021, Oventus Medical entered into a partnership agreement with Aeroflow Healthcare to directly provide Oventus’ OSA treatment solutions, including the O2Vent Optima, to consumers through sleep clinics in the United States.
ResMed, a leading provider of sleep apnea devices, launched a new positive airway pressure (PAP) device in the US sleep apnea devices market in August 2021, aiming to improve the lives of millions of sleep apnea sufferers.
Oventus Medical unveiled the O2Vent Optima in February 2021, a customizable oral appliance therapy device that offers an alternative to continuous positive airway pressure (CPAP) therapy. This product was made available to consumers through GoPAPfree in the United States.
In December 2021, ZOLL Medical Corporation, a subsidiary of Asahi Kasei specializing in medical devices and software solutions, announced the acquisition of Itamar Medical Ltd. Itamar Medical is a company focused on medical devices and digital health, providing home testing services for sleep-related disorders.
Key Questions Answered
What is the size of the sleep apnea market worldwide?
The global sleep apnea devices market was valued at USD 6.74 billion in 2021 and is projected to reach USD 10 billion by 2027.
What is the growth rate of the global sleep apnea devices market?
The global sleep apnea devices market is experiencing a compound annual growth rate (CAGR) of 7.07% from 2021 to 2027.
What are the emerging trends in the sleep apnea devices market?
The sleep apnea devices market is witnessing trends such as the integration of artificial intelligence in treatment, increasing demand for and advancements in home sleep apnea tests (HSATs), adoption of telemedicine and mobile health (mHealth) solutions, and the rising popularity of non-CPAP devices for sleep apnea treatment.
Which companies play a key role in the global sleep apnea devices market?
Key companies in the global sleep apnea devices market include Nihon Kohden Corporation, BMC Medical, Drive DeVilbiss Healthcare, SomnoMed, Glidewell, ResMed, Koninklijke Philips N.V, Fisher & Paykel Healthcare, Compumedics Limited, Inspire Medical Systems, Natus Medical, and Itamar Medical.
What are some popular CPAP devices available in the market?
Some popular CPAP devices available in the sleep apnea devices market include Resmed Airsense 10 CPAP, Z2 Auto Travel CPAP Machine, Resmed Airmini Autoset Travel CPAP Machine, and Devilbiss Intellipap 2 Auto Adjust CPAP.
Which region holds the largest market share in the global sleep apnea devices market?
North America holds the largest market share in the global sleep apnea devices market, accounting for 40.43% of the market. Within North America, the United States is the leading revenue-generating country due to lifestyle changes and sedentary lifestyles prevalent in the country.